Who are Step 2's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): NALBUPHINE HYDROCHLORIDE, Intra thecal morphine., paracetamol codein, PCM/Oxy2, midazolam + pethidine, Standard Opioid.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/step-2.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Step 2 — Competitive Intelligence Brief

Step 2 (Step 2) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid antagonist. Area: Psychiatry.

marketed Opioid antagonist Mu opioid receptor Psychiatry Biologic Live · refreshed every 30 min

Target snapshot

Step 2 (Step 2) — Green Cross Corporation. Step 2 is a medication used to treat opioid use disorder.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Step 2 TARGET	Step 2	Green Cross Corporation	marketed	Opioid antagonist	Mu opioid receptor
NALBUPHINE HYDROCHLORIDE	NALBUPHINE HYDROCHLORIDE		marketed		kappa opioid receptors, mu opioid receptors	1979-01-01
Intra thecal morphine.	Intra thecal morphine.	Ain Shams University	marketed	Opioid agonist	Mu opioid receptor (μ-opioid receptor)
paracetamol codein	paracetamol codein	Diskapi Yildirim Beyazit Education and Research Hospital	marketed	Analgesic combination (paracetamol + opioid)	COX enzymes (paracetamol); mu opioid receptor (codeine)
PCM/Oxy2	PCM/Oxy2	Maastricht University Medical Center	marketed	Opioid analgesic combination	Mu opioid receptor (oxycodone); COX enzymes (paracetamol)
midazolam + pethidine	midazolam + pethidine	Erasme University Hospital	marketed	Benzodiazepine + Opioid combination	GABA-A receptor (midazolam); mu opioid receptor (pethidine)
Standard Opioid	Standard Opioid	Prisma Health-Upstate	marketed	Opioid analgesic	Mu opioid receptor (primary); delta and kappa opioid receptors (secondary)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid antagonist class)

Norwegian University of Science and Technology · 2 drugs in this class
Green Cross Corporation · 1 drug in this class
Middle Tennessee Research Institute · 1 drug in this class
Develco Pharma Schweiz AG · 1 drug in this class
Pacific Institute for Research and Evaluation · 1 drug in this class
Pfizer · 1 drug in this class
NYU Langone Health · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Step 2 — Competitive Intelligence Brief. https://druglandscape.com/ci/step-2. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab